Lineage targets operations into Q2 2028 as it launches COR1 and scales ILT1 manufacturing
Lineage Cell Therapeutics, Inc. · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $1.26
-3.1% in 3d after detection
Post-detection moves
1h
—
1d
+2.3%
3d
-3.1%
7d
+1.6%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS